Cayuga Biotech

About Cayuga Biotech

Cayuga Biotech is a pioneering company in the biotechnology sector, focused on developing innovative treatments for managing excessive bleeding. The company's flagship product, CAY001, is a first-in-class drug designed to accelerate the body's natural clotting response, which is crucial for patients on anticoagulant therapy or those with rare bleeding disorders. Although CAY001 is still in development and has not yet received FDA approval, it aims to address a critical need in emergency medicine where rapid intervention can be life-saving. Cayuga Biotech operates in the healthcare market, targeting hospitals, emergency care units, and specialized clinics as its primary clients. The business model revolves around the research and development of cutting-edge medical treatments, with future revenue streams expected from the commercialization of its products upon regulatory approval. The company is backed by a team of experienced advisors and scientists from prestigious institutions like Harvard Medical School and the University of Michigan Medical School, ensuring a robust scientific foundation for its innovations.